Drug for peripheral T-cell lymphoma granted orphan drug status

fda-logo.jpg

The US FDA has granted orphan drug status to Boston-based Ziopharm Oncology for the company's experimental drug darinaparsin for the treatment of peripheral T-cell lymphoma (PTCL).

Ziopharm will soon begin to recruit patients for a phase I trial of darinaparsin as an added component of the combination chemotherapy regimen CHOP.

Source

Wall Street Journal

LymphomaInfo Social